Skip to main content
. 2024 Oct 1;8:217. doi: 10.1038/s41698-024-00720-9

Fig. 1. ERBB2 mutational profile in newly diagnosed NSCLC patients.

Fig. 1

ERBB2 oncogenic mutations and proportion reported by OncoKB and COSMIC in Geneplus (a, c) and Guardant360 (b, d). e Proportion of ERBB2 oncogenic mutations for 70 patients with co-occurring ERBB2 amplification in Geneplus cohort. f ERBB2 mutational profile of the 70 patients with co-occurring ERBB2 amplification in Geneplus cohort.